Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
N Engl J Med
.
2021 Dec 23;385(26):2485-2487.
doi: 10.1056/NEJMc2115597.
Epub 2021 Nov 3.
Authors
Lindsey R Baden
1
,
Hana M El Sahly
2
,
Brandon Essink
3
,
Dean Follmann
4
,
Kathleen M Neuzil
5
,
Allison August
6
,
Heather Clouting
6
,
Gabrielle Fortier
6
,
Weiping Deng
6
,
Shu Han
6
,
Xiaoping Zhao
6
,
Brett Leav
6
,
Carla Talarico
6
,
Bethany Girard
6
,
Yamuna D Paila
6
,
Joanne E Tomassini
6
,
Florian Schödel
6
,
Rolando Pajon
6
,
Honghong Zhou
6
,
Rituparna Das
6
,
Jacqueline Miller
6
Affiliations
1
Brigham and Women's Hospital, Boston, MA lbaden@bwh.harvard.edu.
2
Baylor College of Medicine, Houston, TX hana.elsahly@bcm.edu.
3
Meridian Clinical Research, Omaha, NE.
4
National Institute of Allergy and Infectious Diseases, Bethesda, MD.
5
University of Maryland, Baltimore, MD.
6
Moderna, Cambridge, MA.
PMID:
34731553
PMCID:
PMC8609569
DOI:
10.1056/NEJMc2115597
No abstract available
Publication types
Letter
Grants and funding
UM1 AI069412/AI/NIAID NIH HHS/United States
UM1 AI068614/AI/NIAID NIH HHS/United States
UM1 AI068618/AI/NIAID NIH HHS/United States
UM1 AI148684/AI/NIAID NIH HHS/United States
UM1 AI068635/AI/NIAID NIH HHS/United States
UM1 AI068619/AI/NIAID NIH HHS/United States
UM1 AI068636/AI/NIAID NIH HHS/United States